Large Cell Lymphoma Diffuse clinical trials

Explore recruiting large cell lymphoma diffuse clinical trials.

Recruiting large cell lymphoma diffuse studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Large Cell Lymphoma Diffuse trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)

Spain, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine- Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL).

Poland, Spain, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BEAR)

Norway, Sweden, Denmark, Finland, Italy, Estonia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma

Spain, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)

Spain, Austria, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Large Cell Lymphoma Diffuse trials by city

Large Cell Lymphoma Diffuse in Toronto Large Cell Lymphoma Diffuse in Vancouver Large Cell Lymphoma Diffuse in Montreal Large Cell Lymphoma Diffuse in Calgary Large Cell Lymphoma Diffuse in Edmonton Large Cell Lymphoma Diffuse in Ottawa Large Cell Lymphoma Diffuse in Winnipeg Large Cell Lymphoma Diffuse in Quebec City Large Cell Lymphoma Diffuse in Hamilton Large Cell Lymphoma Diffuse in Kitchener Large Cell Lymphoma Diffuse in London Large Cell Lymphoma Diffuse in Halifax Large Cell Lymphoma Diffuse in New York Large Cell Lymphoma Diffuse in Los Angeles Large Cell Lymphoma Diffuse in Chicago Large Cell Lymphoma Diffuse in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease